Uridine triacetate (INN),[1] formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine[2] used: Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics.

It was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and approved for use in the United States in 2015.

[9][10][11]

This drug article relating to the gastrointestinal system is a stub.

You can help Wikipedia by expanding it.